Clinical trial
Peptide-pulsed vs. RNA-transfected Dendritic Cell Vaccines in Melanoma Patients
NCT00243529 · Radboud University Medical Center, Other · Completed
Key facts
| NCT number | NCT00243529 |
|---|---|
| Title | Peptide-pulsed vs. RNA-transfected Dendritic Cell Vaccines in Melanoma Patients |
| Official title | In Vivo Responses of DC Vaccines Presenting HLA Class I and II Restricted Tumor Epitopes Either by Peptide-pulsing or mRNA Transfection in Melanoma Patients |
| Lead sponsor | Radboud University Medical Center, Other |
| Collaborators | Dutch Cancer Society |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Melanoma Stage III or IV |
| Intervention type | Biological |
| Interventions | autologous dendritic cell vaccine |
| Enrollment | 64 |
| Start date | Apr 1, 2004 |
| Primary completion | Feb 1, 2009 |
| First posted | Oct 24, 2005 |
| Last update posted | Sep 29, 2009 |
| Countries | Netherlands |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: